Boiron : FY 2023 results down sharply - Very poor visibility (lack of financial details) - TP (€ 39.6 vs € 42) now in line with the takeover bid price
>Revenue/under. op. profit/att. net profit miss consensus expectations - FY 2023 revenue came in at € 493.2m down 7.7% (-6.2% cc, vs. € 534.2m€), the operating profit stood at € 42.3m, down 33.3%, well below expectations (consensus: € 61.4m, ODDO BHF: € 56.7m), i.e 8.6% of revenue (vs. 11.9% in 2022). Attributable net profit worked out at € 35.8m, down 19.8% (consensus: € 44.5m), although investment income was up to € 7.46m (vs. € 1.8m in 2022). Net cash position pl...Boiron manufactures and markets homeopathic medicines. Homeopathic medicines are prepared from vegetable, animal, mineral, or chemical substances, which are diluted. Co. sells three types of products in 59 countries: Non-proprietary homeopathic medicines, OTC family medication specialties, and Other products. There are two large families of homeopathic medicines: Those associated with precise therapeutic indications and dosage, and those that do not mention a therapeutic indication or dosage. Co. supports homeopathy education and training organizations for healthcare professionals. Some of Co.'s brand names include Oscillococcinum®, Stodal®, S?datif PC®, and Coryzalia.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.